home / stock / slgl / slgl quote
Last: | $0.8504 |
---|---|
Change Percent: | -2.35% |
Open: | $0.87 |
Close: | $0.8504 |
High: | $0.8799 |
Low: | $0.82675 |
Volume: | 15,217 |
Last Trade Date Time: | 05/03/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.8504 | $0.87 | $0.8504 | $0.8799 | $0.82675 | 15,217 | 05-03-2024 |
$0.85 | $0.7125 | $0.85 | $0.8898 | $0.7125 | 24,486 | 05-02-2024 |
$0.782 | $0.705 | $0.782 | $0.8679 | $0.682 | 36,286 | 05-01-2024 |
$0.7125 | $0.841 | $0.7125 | $0.8699 | $0.7125 | 42,966 | 04-30-2024 |
$0.8768 | $0.8899 | $0.8768 | $0.8899 | $0.86 | 2,741 | 04-29-2024 |
$0.8896 | $0.861 | $0.8896 | $0.8999 | $0.861 | 3,068 | 04-26-2024 |
$0.861 | $0.92 | $0.861 | $0.9389 | $0.8608 | 92,901 | 04-25-2024 |
$0.92 | $0.93 | $0.92 | $0.99 | $0.92 | 7,563 | 04-24-2024 |
$0.9252 | $0.975 | $0.9252 | $0.975 | $0.9252 | 8,831 | 04-23-2024 |
$0.935 | $0.9122 | $0.935 | $0.935 | $0.9122 | 15,611 | 04-22-2024 |
$0.94 | $0.943 | $0.94 | $1 | $0.8946 | 11,957 | 04-19-2024 |
$0.9001 | $0.8569 | $0.9001 | $0.95 | $0.8569 | 4,553 | 04-18-2024 |
$0.8569 | $0.93 | $0.8569 | $1 | $0.8569 | 17,498 | 04-17-2024 |
$0.9459 | $0.8604 | $0.9459 | $1.05 | $0.8603 | 98,957 | 04-16-2024 |
$0.8605 | $0.9 | $0.8605 | $0.925 | $0.8386 | 4,301 | 04-15-2024 |
$0.840101 | $0.8312 | $0.840101 | $0.840101 | $0.8312 | 4,796 | 04-12-2024 |
$0.840495 | $0.84 | $0.840495 | $0.9297 | $0.84 | 16,469 | 04-11-2024 |
$0.8368 | $0.83 | $0.8368 | $0.869 | $0.804 | 23,043 | 04-10-2024 |
$0.8245 | $0.8594 | $0.8245 | $0.915 | $0.819 | 33,250 | 04-09-2024 |
$0.886 | $0.9739 | $0.886 | $1.04 | $0.79 | 108,473 | 04-08-2024 |
News, Short Squeeze, Breakout and More Instantly...
Sol-Gel Technologies Ltd. Company Name:
SLGL Stock Symbol:
NASDAQ Market:
NESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved lar...
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. ...
Genesco Inc. (GCO) is expected to report $2.66 for Q4 2024 Broadway Financial Corporation (BYFC) is expected to report for quarter end 2023-12-31 Oji Holdings Corporation ADR (OJIPY) is expected to report for Q3 2024 Hibbett Inc. (HIBB) is expected to report $2.54 for Q4 2024 GRI ...